Head-to-head
Ipamorelin vs GHRP-6
Side by side from the same data: half-life, evidence tier, research amounts, common schedule, and every decay curve on one chart.
How they differ
A plain-language read of what actually sets them apart. Reference only, not medical advice.
Both push the body to release growth hormone through the same hunger-hormone switch, but ipamorelin is the cleaner of the two — GHRP-6 also brings on more hunger and raises other hormones. Both are short-acting, gone within a couple of hours. Ipamorelin has a human blood-level study; GHRP-6's injected amounts come from the community.
Side by side
Every figure is drawn from this site's own compound data — the same numbers on each compound's page.
| Measure | Ipamorelin | GHRP-6 |
|---|---|---|
| Category | Growth hormone axis | Growth hormone axis |
| Evidence | A · Tested in people | B · Some human use |
| Route | Intravenous | Subcutaneous |
| Half-life | 2 h | 0.3 h |
| Typical vial | 5 / 10 mg | 5 / 10 mg |
| Research amount | 100–300 mcg | 100–200 mcg |
| Common schedule | Every day | Twice a day |
| Cycle / break | 8–12 / 4 | — |
| Studied for | Growth-hormone release | Growth-hormone release |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Every compound on one chart — something the single-compound pages cannot show.
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.